SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Kyverna Therapeutics Announces Completion Of BLA Submission For Miv-Cel In Stiff Person Syndrome And Reports Third Quarter 2026 Financial Re

Kyverna Therapeutics, Inc. NASDAQ:KYTX

KYTX

Related stories